ArticleGlycoconjugate journal2025
High molecular weight fucosylated glycosaminoglycan promotes the binding of antithrombin and thrombin: a template mechanism and structure-activity relationship study.
Article in Glycoconjugate journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Native fucosylated glycosaminoglycan (FG), a structurally unique polysaccharide with chondroitin sulfate like backbone and sulfated fucose side chains, has multiple anticoagulant mechanisms. Analyzing the interaction between FG and coagulation proteins will help to further understand its pharmacological mechanisms. Previously, we have reported that high molecular weight depolymerized FG (dFG) and unfractionated heparin (UFH) exhibit different binding models for antithrombin (AT), which is a primary natural anticoagulant in plasma by inhibiting coagulation proteases including thrombin (FIIa). In this study, the effect of dFG or UFH on the interaction between AT and FIIa was detected by biolayer interferometry. The relative AT binding affinity and AT-dependent anti-FIIa activity of dFG derivatives were measured to elucidate the structure-activity relationship. The results demonstrate that high molecular weight dFG significantly promotes the irreversible binding of FIIa and AT by a template mechanism. As the molecular weight decreases, the relative AT binding affinity of dFG decreases and molecular weight above 8.55 kDa is required for their interaction in this study. Both the fucose side chains and carboxyl groups are indispensable for dFG to bind with AT and inhibit FIIa activity. This study clarifies the mechanism and structure-activity relationship of dFG inhibiting FIIa by AT, providing references for the development of novel anticoagulant drugs based on FG and its derivatives.
Indexed as
Identifiers
41432835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.